Posts Tagged ‘awards’

Spin-out Success for Manchester at the 11th Northwest Biomedical Awards

Written by UMIP on . Posted in News

Over 200 people from the Northwest’s biomedical sector gathered last night (Thursday 24th November) at the 11th Northwest Biomedical Awards at Mere Golf and Country Club. This prestigious awards dinner celebrates key achievements from companies and individuals who have made a significant contribution to the biomedical sector during 2011.

The awards, organised by Bionow, were a resounding success and showcased the very best of the region’s world-class biotechnology sector.

The Manchester winners were:

Conformetrix Ltd – Emerging Biomedical Technology Project of the Year.

Myconostica Ltd – Biomedical Project of the Year.

Qiagen Manchester Ltd – Company of the Year.

Shortlisted for Biomedical Product or Service of the Year was Phagenesis Ltd. Epistem was shortlisted for Emerging Biomedical Technology Project of the Year.

Shortlisted for Healthcare Project of the Year was Paul Malone, Medical and Human Sciences, and Neil Dixon from The School of Chemistry was shortlisted for Promising Biomedical Technologist of the Year.

Other winners on the night included Microvisk Technologies (Healthcare Project of the Year), Jonathan Souquet, Eden Biodesign (Promising Biomedical Technologist of the Year), Redx Pharma (Start-up of the Year) and Sky Medical Technology (Biomedical Product or Service of the Year).

UMIP - REPUTATION AND VALUE THROUGH INTELLECTUAL PROPERTY®

Privacy Policy / Terms and Conditions / ┬ę Copyright 2015 The University of Manchester Intellectual Property / Created by HTP Digital Marketing Agency

The University of Manchester Intellectual Property ("UMIP") acts solely as agent for the University in relation to any matter relating to intellectual property ("IP") and know how created at the University. This is whether such IP is created by employees, students or others. UMIP does not represent anyone else in such matters. If anyone else requires advice in relation to such IP then they must take their own independent legal advice.